Silo Pharma - נכסים נקיים למניה בודדת SILO

Silo Pharma, Inc. (SILO) is developing psilocybin-based drugs to combat PTSD and Alzheimer's disease. Management is betting on microdosing to treat inflammatory processes in the nervous system. Business success depends on clinical trials of antidepressants and stable R&D funding. The actual book value per share has settled at 4.31, as clearly demonstrated by the price action on this chart.

Book value per share determines the residual tangible value of capital minus all liabilities, serving as a measure of an investor's real assets. When analyzing the book value of capital per share for Silo Pharma, Inc. (SILO), it is essential to consider that intangible assets and intellectual property play a key role in the biopharmaceutical sector, as they are critical for navigating R&D phases and securing FDA approval.